On 2014 Aug 27, Jorge H Ramírez commented:

I recently mentioned the RE-LY study in a previous comment yesterday via PubMed Commons. http://www.ncbi.nlm.nih.gov/pubmed/25138329#cm25138329_5938

This will be also my last comment via PubMed commons related to dabigatran or the RE-LY study (the only exception are possible replies to comments related to these posts).

Information about dabigatran & the RE-LY study

1. Cohen Deborah. Concerns over data in key dabigatran trial BMJ 2014; 349:g4747

2. Cohen Deborah. Dabigatran: how the drug company withheld important analyses BMJ 2014; 349:g4670

3. Moore Thomas J, Cohen Michael R, Mattison Donald R. Dabigatran, bleeding, and the regulators BMJ 2014; 349:g4517

4. Charlton Blake, Redberg Rita. The trouble with dabigatran BMJ 2014; 349:g4681

5. Jackson Trevor. Dabigatran and statins: faith, hype, and transparency BMJ 2014; 349:g4793

6. Ramirez, Jorge H (2014): Requested (Jul 29, 2014) & Retracted by the author (Aug 23, 2014): "Conelly S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2009; 361:1139-1151"] - Question Thread Open. figshare. http://dx.doi.org/10.6084/m9.figshare.1144305

7. Bleeding with dabigatran, rivaroxaban, apixaban. Prescrire Int 2013; 22 (139): 155-159.

8. Dabigatran for atrial fibrillation: why we can not rely on RE-LY http://www.ti.ubc.ca/sites/ti.ubc.ca/files/80.pdf

9. The use, misuse and abuse of dabigatran https://www.mja.com.au/journal/2013/198/7/use-misuse-and-abuse-dabigatran

10. Ramirez, Jorge H (2014): Dabigatran (Pradaxa): 81.4% of registered studies in ClinicalTrials.gov are unpublished. figshare. http://dx.doi.org/10.6084/m9.figshare.1116303

Competing interests: Already declared in previous comment posted in PubMed commons (1st URL above)

On 2014 Aug 27, Jorge H Ramírez commented:

I recently mentioned the RE-LY study in a previous comment yesterday via PubMed Commons. http://www.ncbi.nlm.nih.gov/pubmed/25138329#cm25138329_5938

This will be also my last comment via PubMed commons related to dabigatran or the RE-LY study (the only exception are possible replies to comments related to these posts).

Information about dabigatran & the RE-LY study

1. Cohen Deborah. Concerns over data in key dabigatran trial BMJ 2014; 349:g4747

2. Cohen Deborah. Dabigatran: how the drug company withheld important analyses BMJ 2014; 349:g4670

3. Moore Thomas J, Cohen Michael R, Mattison Donald R. Dabigatran, bleeding, and the regulators BMJ 2014; 349:g4517

4. Charlton Blake, Redberg Rita. The trouble with dabigatran BMJ 2014; 349:g4681

5. Jackson Trevor. Dabigatran and statins: faith, hype, and transparency BMJ 2014; 349:g4793

6. Ramirez, Jorge H (2014): Requested (Jul 29, 2014) & Retracted by the author (Aug 23, 2014): "Conelly S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2009; 361:1139-1151"] - Question Thread Open. figshare. http://dx.doi.org/10.6084/m9.figshare.1144305

7. Bleeding with dabigatran, rivaroxaban, apixaban. Prescrire Int 2013; 22 (139): 155-159.

8. Dabigatran for atrial fibrillation: why we can not rely on RE-LY http://www.ti.ubc.ca/sites/ti.ubc.ca/files/80.pdf

9. The use, misuse and abuse of dabigatran https://www.mja.com.au/journal/2013/198/7/use-misuse-and-abuse-dabigatran

10. Ramirez, Jorge H (2014): Dabigatran (Pradaxa): 81.4% of registered studies in ClinicalTrials.gov are unpublished. figshare. http://dx.doi.org/10.6084/m9.figshare.1116303

Competing interests: Already declared in previous comment posted in PubMed commons (1st URL above)